{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chiang NJ"],"funding":["National Health Research Institutes, Taiwan","Ministry of Science and Technology","Taiwan Cancer Clinic Foundation and Melissa Lee Cancer Foundation","Ono Pharmaceutical Co., Ltd.","Taiwan Upper Gastrointestinal Cancers Clinical Trial Consortium","National Institute of Cancer Research","Taiwan Cooperative Oncology Group"],"pagination":["4248-4257"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9527499"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(19)"],"pubmed_abstract":["<h4>Purpose</h4>Modified gemcitabine and S-1 (GS) is an active regimen for patients with advanced biliary tract cancer (ABTC) in our previous study. Herein, we report the results of a single-arm phase II of nivolumab plus modified GS (NGS) as first-line treatment in ABTC.<h4>Patients and methods</h4>Patients received nivolumab 240 mg and 800 mg/m2 gemcitabine on day 1 plus daily 80/100/120 mg of S-1 (based on body surface area) on days 1 to 10, in a 2-week cycle. The primary endpoint was the objective response rate (ORR). The correlation between therapeutic efficacy and genetic alterations with signatures identified by targeted next-generation sequencing panels was explored.<h4>Results</h4>Between December 2019 and December 2020, 48 eligible patients were enrolled. After a median of 17.6 m"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study."],"pmcid":["PMC9527499"],"funding_grant_id":["CA-109-PP-72","CA-108-PP-67","MOST109–2314-B-075–082-MY3","CA-110-PP-37","C08–022","CA-110-PP-22","109–2321-B-006–011","MOHW110-TDU-B-211–124003","CA-109-PP-23"],"pubmed_authors":["Hsiao CF","Chen LT","Lee IC","Bai LY","Tan KT","Lee PC","Huang CJ","Yeh CN","Chen SJ","Chiang NJ","Huang YH","Hung YP","Chen MH","Chao Y","Huang CY","Chen SC","Su YY","Shan YS"],"additional_accession":[]},"is_claimable":false,"name":"Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study.","description":"<h4>Purpose</h4>Modified gemcitabine and S-1 (GS) is an active regimen for patients with advanced biliary tract cancer (ABTC) in our previous study. Herein, we report the results of a single-arm phase II of nivolumab plus modified GS (NGS) as first-line treatment in ABTC.<h4>Patients and methods</h4>Patients received nivolumab 240 mg and 800 mg/m2 gemcitabine on day 1 plus daily 80/100/120 mg of S-1 (based on body surface area) on days 1 to 10, in a 2-week cycle. The primary endpoint was the objective response rate (ORR). The correlation between therapeutic efficacy and genetic alterations with signatures identified by targeted next-generation sequencing panels was explored.<h4>Results</h4>Between December 2019 and December 2020, 48 eligible patients were enrolled. After a median of 17.6 m","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-07-14T21:08:49.299Z","creation":"2025-04-06T00:53:25.225Z"},"accession":"S-EPMC9527499","cross_references":{"pubmed":["35849151"],"doi":["10.1158/1078-0432.CCR-22-1152"]}}